X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KSQ-001EX consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. It is being evaluated for the treatment of advanced solid tumors including head and neck cancer, melanoma & lung cancer.
Lead Product(s): KSQ-001EX
Therapeutic Area: Oncology Product Name: KSQ-001EX
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
The collaboration aims to expedite the development of KSQ's two lead engineered tumor-infiltrating lymphocyte programs, a single-edit eTIL that deletes the SOCS1 gene, and KSQ-004EX, a dual-edit eTIL that deletes both the SOCS1 and Regnase-1 genes, for solid tumors.
Lead Product(s): KSQ-001EX
Therapeutic Area: Oncology Product Name: KSQ-001EX
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CTMC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 06, 2023
Details:
The agreement aims for the development and commercialization of KSQ-4279, a first-in-class, potent, and selective small molecule inhibitor of USP1, in a Phase 1 clinical trial for the treatment of solid tumors.
Lead Product(s): KSQ-4279
Therapeutic Area: Oncology Product Name: KSQ-4279
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 13, 2023
Details:
The expanded collaboration is focused on novel tumor-intrinsic natural killer (NK) and T-cell targets discovery and validation to inform the development of targeted therapies in cancer by using KSQ's proprietary CRISPRomics® platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $510.0 million Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration May 17, 2023
Details:
Under the terms of the agreement, acquisition of multiple research-stage DNA damage response (DDR) programs identified using KSQ’s CRISPRomics platform technology will advance identification of novel oncology targets and develop potential first-in-class programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 25, 2023
Details:
KSQ-4279 is a first-in-class small molecule targeting USP1, a protein regulating DNA damage response (DDR). USP1 was identified by KSQ's CRISPRomics platform as a novel synthetic lethal target in cancers with certain types of genomic instability.
Lead Product(s): KSQ-4279,Undisclosed
Therapeutic Area: Oncology Product Name: KSQ-4279
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
KSQ-4279, a potent and selective USP1 inhibitor, has a unique mode of allosteric binding to USP1 and a high degree of selectivity over other family members, in patients with advanced solid tumors.
Lead Product(s): KSQ-4279,Undisclosed
Therapeutic Area: Oncology Product Name: KSQ-4279
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Under the agreement, KSQ has granted Takeda an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize cell and non-cell therapy products that modulate targets identified using KSQ’s CRISPRomics technology.
Lead Product(s): KSQ-4279
Therapeutic Area: Oncology Product Name: KSQ-4279
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $1,700.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2021
Details:
Preclinical data on the company’s USP1 inhibitor program will be featured as part of a plenary session highlighting late breaking and best proffered papers, and the company will also present a poster featuring data on its lead USP1 candidate, KSQ-4279.
Lead Product(s): KSQ-4279
Therapeutic Area: Oncology Product Name: KSQ-4279
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
Data demonstrate potential to increase efficacy of TIL adoptive cell therapy in preclinical models.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
